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Abstract
The expression of P53, Bcl-2, Bax, Bag-1, and Mcl-1 proteins in CD5/
CD20-positive B-chronic lymphocytic leukemia (B-CLL) cells from
30 typical CLL patients was evaluated before and after 48 h of
incubation with 10-6 M fludarabine using multiparametric flow
cytometric analysis. Protein expression was correlated with annexin V
expression, Rai modified clinical staging, lymphocyte doubling time,
and previous treatment. Our main goal was to determine the predictive
value of these proteins in CLL cells in terms of disease evolution. Bcl-
2 expression decreased from a median fluorescence index (MFI) of
331.71 ± 42.2 to 245.81 ± 52.2 (P < 0.001) after fludarabine treatment,
but there was no difference between viable cells (331.57 ± 44.6 MFI)
and apoptotic cells (331.71 ± 42.2 MFI) before incubation (P = 0.859).
Bax expression was higher in viable cells (156.24 ± 32.2 MFI) than in
apoptotic cells (133.56 ± 35.7 MFI) before incubation, probably
reflecting defective apoptosis in CLL (P = 0.001). Mcl-1 expression
was increased in fludarabine-resistant cells and seemed to be a re-
markable protein for the inhibition of the apoptotic process in CLL
(from 233.59 ± 29.8 to 252.04 ± 35.5; P = 0.033). After fludarabine
treatment, Bag-1 expression was increased in fludarabine-resistant
cells (from 425.55 ± 39.3 to 447.49 ± 34.5 MFI, P = 0.012), and
interestingly, this higher expression occurred in patients who had a
short lymphocyte doubling time (P = 0.022). Therefore, we could
assume that Bag-1 expression in such situation might identify CLL
patients who will need treatment earlier.
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Introduction
B-cell chronic lymphocytic leukemia (B-
CLL) is a neoplasm that results in the accu-
mulation of clonal CD5-positive B-cells with
a low proliferation rate (1). In most patients,
the circulating mature B-lymphocytes are
largely quiescent G0 phase cells, which ac-
cumulate due to longer survival than normal
B cells rather than to increased proliferation
(2). Thus, B-CLL represents an example of a
malignancy caused by failure of programmed
cell death (3).
Bcl-2 was first described in follicular lym-
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phomas with t(14;18) translocation (4). At
least 20 different Bcl-2 family members have
been reported, acting as death antagonist or
agonist proteins. Group I Bcl-2 proteins can
form heterodimers with group II and prevent
the occurrence of programmed cell death (5).
The mcl-1 gene encodes a 37-kDa protein with
significant homology to Bcl-2, particularly in
the carboxyl portion. At least in vitro, Mcl-1
has functions similar to those of Bcl-2, having
the ability to heterodimerize with Bax and to
neutralize Bax-mediated cytotoxicity (6). Bag-
1 was first cloned from mouse cells as a novel
protein which interacts with Bcl-2 and Bcl-XL,
enhancing the ability of Bcl-2 to prevent apop-
tosis. Four protein isoforms with 50 (p50), 46
(p46), 33 (p33), and 29 kDa (p29) molecular
masses have been described. Bag-1 interacts
with the serine/threonine-specific protein ki-
nase Raf-1 and stimulates its activity through
a Ras-independent mechanism; m-RNA of
Bag-1 binds to platelet-derived growth factor,
increasing its ability to inhibit apoptosis (7).
Mutations of the p53 tumor suppressor gene
may facilitate genetic damage transmission
and the emergence of neoplastic clones with
survival advantage. Mutations of the p53 gene
occur in 15% of B-CLL patients (8).
Fludarabine, a potent apoptosis-induc-
ing drug, is useful for the treatment of indo-
lent lymphoproliferative disorders. F-ara-A,
in its fludarabine nucleoside form, is trans-
ported into the cells and converted to F-ara-
ATP, an active metabolite for cell enzymes.
The exact mechanism of apoptosis induction
by F-ara-A in proliferative and quiescent
cells has not been completely established;
however, some data suggest that purine
nucleoside analogs may also function as ac-
tivators for d-ATP-dependent caspase path-
ways (9,10).
We evaluated in vitro, the expression of
P53, Bcl-2, Bax, Bag-1, and Mcl-1 proteins
in CD5-positive B-CLL cells in 30 typical
CLL patients on two different occasions,
i.e., before and after 48 h of fludarabine
incubation. The protein expressions were
correlated with annexin V expression, Rai
modified clinical staging, lymphocyte dou-
bling time (LDT), and the presence of previ-
ous treatment. Our main goal was to deter-
mine the value of these apoptotic proteins in
CLL cells in order to predict the evolution of
the disease.
Material and Methods
Patients
Thirty B-CLL patients, 8 women and 22
men with a median age of 68 years (range: 31
to 87 years) were studied. All patients fulfilled
the National Cancer Institute criteria for the
diagnosis of CLL. Fourteen patients had re-
ceived previous therapies, but all had been off
any treatment for at least one month before the
study (11). Clinical staging was done accord-
ing to the criteria of Rai and Montserrat (12).
LDT was defined as the time needed to reach
a double lymphocyte count in relation to the
previous evaluation (Table 1) (13). The study
was approved by the Institutional Ethics Re-
view Board of the Medical School, Federal
University of São Paulo, São Paulo, SP, Bra-
zil, and subjects gave written informed con-
sent to participate.
Lymphocyte isolation and cell culture
Peripheral blood mononuclear cells were
isolated by density gradient centrifugation
using Lymphoprep (Nycomed, Oslo, Nor-
way) (14). Freshly isolated mononuclear
cells, 1 x 106/mL, were incubated in RPMI
1640/2 mM-glutamine medium (Gibco-BRL,
Gaithersburg, MD, USA) and supplemented
with 50 IU/mL penicillin, 100 µg/mL strep-
tomycin, 20% fetal calf serum, and 10-6 M
fludarabine for 48 h at 37ºC in a humidified
5% CO2 atmosphere.
Bcl-2, Bax, Bag-1, Mcl-1, and P53 analysis
The following monoclonal antibodies
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were used: Bcl-2 and P53 (Dako A/S, Glos-
trup, Denmark), Bax, Mcl-1 and Bag-1 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), and CD5 and CD20 (Becton Dickin-
son, San Jose, CA, USA). CD5 was conju-
gated with phycoerythrin, CD20 with peridin
chlorophyl, Bcl-2 and P53 with fluorescein
isothiocyanate (FITC) and the others were
pure lyophilized monoclonal antibodies
(MoAb). As a negative control, isotype-
matched immunoglobulins were used for
each MoAb studied. Briefly, 1 x 106 cells
were first stained with CD5/phycoerythrin
and CD20/peridin chlorophyl. After per-
meabilization and fixation using a Fix and
Perm kit (CALTAG, San Francisco, CA, USA),
the cells were stained with P53/FITC and Bcl-
2/FITC or Bax, Bag-1 and Mcl-1. For the last
three MoAb, a second FITC-conjugated anti-
rabbit immunoglobulin antibody (Dako) was
used. Data acquisition and analysis were per-
formed by FACScalibur flow cytometer
(Becton Dickinson). The median fluorescence
index (MFI) was recorded in a linear mode (0-
1023), as previously described (15,16).
Evaluation of in vitro apoptosis
Double staining for cellular annexin and
DNA was done using the annexin-V-fluo-
rescein kit (Roche/Boehringer-Mannheim,
Penzburg, Bayern, Germany). The cells in
HEPES buffer (part of the kit) were incu-
bated with FITC-annexin and propidium io-
dide and acquisition and analysis were per-
formed by flow cytometry (17). Morpho-
logical changes in cells undergoing apopto-
sis affect their light-scattering properties
causing a reduction in their size and an in-
crease in their complexity. These changes
were used for gating apoptotic and viable
cells. The expression of proteins and annexin
was determined in the apoptotic and viable
cells (18).
Statistical analysis
Data for mean protein expression by vi-
able and apoptotic cells were compared by
ANOVA before and after fludarabine incu-
bation. ANOVA was also used to determine
Table 1. Characteristics of the 30 patients according to previous treatment at the time of analysis.
Characteristic Treated patients Untreated patients Total
Sex
Male 10 (34%) 12 (40%) 22 (74%)
Female 4 (13%) 4 (13%) 8 (26%)
Age (years)
Median 67 74 68
Range 58-78 31-87 31-87
Rai clinical stage
0 (low risk) 4 (13.3%) 7 (23.3%) 11 (36.6%)
I or II (intermediate risk) 5 (16.6%) 5 (16.6%) 10 (33.3%)
III or IV (high risk) 5 (16.6%) 4 (13.3%) 9 (30.0%)
Lymphocyte count (per mm3)
Median 7,800 39,000 31,661
Range 6,000-500,000 60,000-123,430 6,000-500,000
Platelet count (per mm3)
Median 88,000 128,000 136,000
Range 77,000-204,000 101,000-340,000 77,000-340,000
Hemoglobin (g/dL)
Median 12.8 12.8 13.3
Range 8.4-15.2 7.4-17.0 7.4-17.0
Clinical staging according to criteria of Rai and Montserrat (12): 0 (lymphocytosis in blood and marrow only);
I (lymphocytosis + lymphadenopathy); II (lymphocytosis + splenomegaly + hepatomegaly); III (lymphocytosis
+ anemia), and IV (lymphocytosis + thrombocytopenia).
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significant differences between Rai stages,
LDT (high and low) and the patients’ previ-
ous treatment.
Results
Comparison of protein expression by viable
cells before and after fludarabine incubation
(Table 2)
After incubation with fludarabine P53
expression increased from 14.54 ± 2.0 to
26.40 ± 8.9 MFI (P = 0.003), Bag-1 expres-
sion increased from 425.55 ± 39.3 to 447.49
± 34.5 MFI (P = 0.012), Mcl-1 expression
increased from 233.59 ± 29.8 to 252.04 ±
35.5 MFI (P = 0.033), and annexin expres-
sion increased from 4.43 ± 3.17 to 19.73 ±
9.0% (P < 0.001). Bax expression did not
differ significantly before (156.24 ± 32.2
MFI) and after (167.25 ± 26.6 MFI) incuba-
tion with fludarabine (P = 0.169).
Bag-1 expression increased from 430.69
± 41.2 to 437.03 ± 37.22 within the long
LDT group, while Bag-1 expression in-
creased from 420.78 ± 42.6 to 465.93 ±
Table 2. Comparison of protein expression (MFI) before and after fludarabine incubation in viable and
apoptotic cells.
Protein Before incubation After incubation P (before vs after) P (Rai) P (LDT) P (Treat)
Protein expression in viable cells
P53 14.54 ± 2.0 26.40 ± 8.9 0.003 0.816 0.470 0.430
Bcl-2 331.57 ± 44.6 324.09 ± 41.4 0.313 0.369 0.123 0.777
Bax 156.24 ± 32.2 167.25 ± 26.6 0.169 0.785 0.129 0.890
Bag-1 425.55 ± 39.3 447.49 ± 34.5 0.012 0.634 0.022 0.978
Mcl-1 233.59 ± 29.8 252.04 ± 35.5 0.033 0.640 0.206 0.588
Bcl2/Bax 2.23 ± 0.7 1.97 ± 0.3 0.112 0.346 0.063 0.900
Annexin 4.43 ± 3.17 19.73 ± 9.0 <0.001 0.093 0.132 0.467
Protein expression in apoptotic cells
P53 6.46 ± 1.4 15.32 ± 9.2 0.018 0.062 0.324 0.651
Bcl-2 331.71 ± 42.2 245.81 ± 52.2 <0.001 0.136 0.351 0.015
Bax 133.56 ± 35.7 154.33 ± 37.4 0.050 0.870 0.110 0.389
Bag-1 379.29 ± 57.9 394.87 ± 78.3 0.455 0.869 0.256 0.840
Mcl-1 241.15 ± 44.0 204.28 ± 43.0 0.009 0.960 0.319 0.331
Bcl2/Bax 2.64 ± 0.7 1.67 ± 0.5 <0.001 0.689 0.054 0.226
Annexin 74.81 ± 20.8 86.91 ± 11.2 <0.001 0.827 0.358 0.620
Data are reported as means ± SD. MFI = mean fluorescence index; Rai = clinical staging (Ref. 12); LDT =
lymphocyte doubling time; Treat = mean protein expression in patients who had received previous treatment.
Table 3. Comparison of protein expression (MFI) between viable and apoptotic cells before fludarabine
incubation.
Protein Viable cells Apoptotic cells P (viable vs apoptotic) P (Rai) P (LDT) P (Treat)
P53 14.54 ± 2.0 6.46 ± 1.4 0.190 0.212 0.190 0.666
Bcl-2 331.57 ± 44.6 331.71 ± 42.2 0.859 0.416 0.907 0.642
Bax 156.24 ± 32.2 133.56 ± 35.7 0.001 0.757 0.784 0.696
Bag-1 425.55 ± 39.3 379.29 ± 57.9 <0.001 0.812 0.964 0.348
Mcl-1 233.59 ± 29.8 241.15 ± 44.0 0.251 0.738 0.862 0.534
Bcl2/Bax 2.23 ± 0.7 2.64 ± 0.7 0.002 0.386 0.661 0.641
Annexin 4.43 ± 3.17 74.81 ± 20.8 <0.001 0.696 0.505 0.843
Data are reported as means ± SD. MFI = mean fluorescence index; Rai = clinical staging (Ref. 12); LDT =
lymphocyte doubling time; Treat = mean protein expression in patients who had received previous treatment.
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27.87 within the short LDT group. There-
fore, Bag-1 presented a higher increase within
the short LDT group (P = 0.022). Other
proteins did not show significant variance
when analyzed within the LDT group, the
Rai modified stage group or the previous
treatment group.
Comparison of protein expression by
apoptotic cells before and after incubation
with fludarabine (Table 2)
P53 expression increased from 6.46 ±
1.4 to 15.32 ± 9.2 MFI (P = 0.018), Bcl-2
expression decreased from 331.71 ± 42.2 to
245.81 ± 52.2 MFI (P < 0.001), Bax expres-
sion increased from 133.56 ± 35.7 to 154.33
± 37.4 MFI (P = 0.050), and Mcl-1 expres-
sion decreased from 241.15 ± 44.0 to 204.28
± 43.0 MFI (P = 0.009). Expression of the
Bcl-2/Bax index decreased from 2.64 ± 0.7
to 1.67 ± 0.5 (P < 0.001) and annexin expres-
sion increased from 74.81 ± 20.8 to 86.91 ±
11.2% (P < 0.001).
Bcl-2 expression decreased from 332.74
± 45.4 to 266.10 ± 49.6 within the untreated
patient group and from 330.80 ± 40.7 to
228.05 ± 49.2 within the treated patient group.
Therefore, Bcl-2 expression decreased more
within the treated than the untreated group
(P = 0.015). Other proteins did not show
significant variance when analyzed within
the previous treatment group, the Rai modi-
fied stage group or the LDT group.
Comparison of protein expression between
viable and apoptotic cells before incubation
with fludarabine (Table 3)
Bax expression was higher in viable cells
(156.24 ± 32.2 MFI) than in apoptotic cells
(133.56 ± 35.7 MFI, P = 0.001). Bag-1 ex-
pression was higher in viable cells (425.55 ±
39.3 MFI) than in apoptotic cells (379.29 ±
57.9 MFI, P < 0.001) and the Bcl-2/Bax
index was lower in viable cells (2.23 ± 0.7)
than in apoptotic cells (2.64 ± 0.7, P = 0.002).
Annexin expression was lower (4.43 ±
3.17%) in viable cells than in apoptotic cells
(74.81 ± 20.8%, P < 0.001) and Bcl-2 ex-
pression was not significantly different be-
tween viable (331.57 ± 42.2 MFI) and apop-
totic cells (331.71 ± 42.2 MFI, P = 0.859).
None of the other proteins were significantly
modified when analyzed within the LDT
group, the Rai modified stage group or the
previous treatment group.
Comparison of protein expression be-
tween viable and apoptotic cells after flu-
darabine incubation did not present relevant
information and will not be discussed.
Discussion
We demonstrated an increase of annexin
expression in viable (P < 0.001; Table 2) and
apoptotic (P < 0.001; Table 2) cells by com-
paring CLL cells before and after fludarabine
treatment (Figure 1).
There was a reduction of Bcl-2 expres-
sion after fludarabine treatment of apoptotic
Figure 1. Significant modifications in the protein expressions before and after fludarabine
incubation.
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cells (P < 0.001; Table 2). On the other hand,
untreated patients presented higher expres-
sion in these cells than treated patients (P =
0.015; Table 2). Therefore, we postulate that
previous treatment might have reduced Bcl-
2 expression by inducing CLL cells to apop-
tosis.
Comparison of viable and apoptotic cells
showed a higher Bcl-2/Bax index in apopto-
tic cells before fludarabine treatment (spon-
taneous apoptosis) as a consequence of a
lower Bax expression (P = 0.002; Table 3).
These findings suggest a greater involve-
ment of Bax in spontaneous apoptosis. There-
fore, we can assume that the Bcl/Bax index
better reflects the apoptosis process than
isolated Bcl-2 level.
Analysis of the Bag-1 protein disclosed
important features, and probably it is the
most remarkable finding in our study. Lower
Bag-1 expression was observed in viable
cells than in apoptotic cells in pre-fludarabine
incubations (P < 0.001; Table 3). The com-
parison of viable cells before and after
fludarabine indicated an increase of Bag-1
after incubation (P = 0.012; Table 2). These
results suggested that Bag-1 is a remarkable
mechanism for cell survival after fludarabine
treatment. Also, Bag-1 increased in patients
with shorter LDT (P = 0.022; Table 2, Figure
2), as confirmed by ANOVA, particularly
observed in viable cells resistant to fludara-
bine. Kitada et al. (6) linked high Bag-1
protein levels to a poor treatment response,
suggesting that Bag-1 and Bcl-2 interactions
enhance resistance to apoptosis. Plate et al.
(19) unexpectedly observed that some anti-
apoptotic genes such as bag and akt were
positively regulated in CLL cells after treat-
ment with fludarabine. They concluded that
Bag-1 is a protein associated with cell sur-
vival which interacts with Bcl-2, increasing
its effectiveness. This seems to be important
because Bcl-2 alone cannot inhibit all apop-
totic pathways triggered to remove cells from
the organism. However, it should be taken
into account that the increase of Bag-1 in
cases of reduced LDT was seen mainly in
viable cells after fludarabine incubation. It
was notable that in this situation Bag-1 can
be used to identify patients who will present
short LDT and might have some influence in
determining those patients who will need
early therapeutic measures.
Mcl-1 protein expression was increased
in fludarabine-resistant cells (P < 0.033;
Table 2) and decreased in apoptotic cells (P
= 0.009; Table 3). Most Mcl-1 studies have
been conducted on non-lymphoid cells,
showing that Mcl-1 expression is induced by
IL-4 and inhibited by TGF-ß. Bcl-2 and
Mcl-1 are able to form heterodimers with
Bax and then neutralize their activities. High
Mcl-1 levels were associated with poor re-
mission achievement (6). However, we could
not associate Mcl-1 protein expression with
LDT, prior treatment, or Rai modified stage.
P53 is a highly unstable protein with a
very short half-life in cell culture. However,
P53 accumulates after cell exposures to
DNA-damaging agents such as doxorubicin,
5-fluoruracil, etoposide, and ion radiation
(20). P53 protein expression has been corre-
Figure 2. Comparison of patients with short and long lymphocyte doubling time (LDT)
regarding Bag-1 expression before and after fludarabine incubation.
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lated with progressive disease when high
protein levels are caused by p53 gene muta-
tion (21). Our results revealed P53 protein
up-regulation after fludarabine incubation
in the viable (P = 0.003; Table 2) and apop-
totic (P = 0.018; Table 2) cells. Since we did
not find a relation between P53 expression
and LDT, staging or treatment, our results
agree with data reported in other studies
which did not evaluate p53 gene mutation
(22,23).
In the present study we have shown that:
1) Bax protein was important to induce pro-
grammed cell death seen in the apoptotic
cells after incubation with fludarabine, 2)
the Bcl-2/Bax index indicated apoptotic char-
acteristics better than Bcl-2 itself, 3) the
Mcl-1 protein found in resistant cells may be
one of the proteins responsible for apoptosis
inhibition in CLL patients, and 4) Bag-1
protein presented high expression in viable
cells after fludarabine incubation, indicating
that Bag-1 is the most important protein in
apoptosis resistance. Its determination can
predict CLL patients who demonstrate a short
LDT and indicate who will need early therapy.
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